



March 10, 2020

Supporting a study to evaluate the efficacy and safety of Pirfenidone  
for the novel Coronavirus infection

GNI Group Ltd. is pleased to report that our consolidated subsidiary Beijing Continent Pharmaceutical Co., Ltd is supporting the Tongji Hospital of Wuhan for its clinical study to evaluate the efficacy and safety of Pirfenidone for the novel Coronavirus infection.